AUTHOR=Wu Chenghao , Yu Shaobo , Wang Yanzhong , Gao Yuzhen , Xie Xinyou , Zhang Jun TITLE=Metabolic-suppressed cancer-associated fibroblasts limit the immune environment and survival in colorectal cancer with liver metastasis JOURNAL=Frontiers in Pharmacology VOLUME=Volume 14 - 2023 YEAR=2023 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1212420 DOI=10.3389/fphar.2023.1212420 ISSN=1663-9812 ABSTRACT=Background: Colorectal cancer liver metastasis is a major risk factor of poor outcomes, necessitating proactive interventions and treatments. Cancer-associated fibroblasts (CAFs) play essential roles in metastasis, with a focus on metabolic reprogramming.However, knowledge about associations between CAF metabolic phenotypes and immune cell is limited. This study uses single-cell and bulk transcriptomics data to decode roles of metabolism-related subtype of CAFs and immune cells in liver metastasis, developing a CAF-related prognostic model for colorectal cancer liver metastases.Methods: In this study, CAF metabolism-related phenotypes were screened using comprehensive datasets from The Cancer Genome Atlas and gene expression omnibus (GEO). Cox regression and Lasso regression were applied to identify prognostic genes related to CAFs, and a model was constructed based on the CAF subtype gene score.Subsequently, functional, immunological, and clinical analyses were performed.The study demonstrated the metabotropic heterogeneity of CAF cells. CAF cells with varying metabolic states were found to exhibit significant differences in communications with different immune cells. Prognostic features based on CAF signature scores were found to be useful in determining the prognostic status of colorectal cancer patients with liver metastases. High immune activity and an enrichment of tumor-related pathways were observed in samples with high CAF signature scores. Furthermore, CAF signature score could be practical in guiding the selection of chemotherapeutic agents with higher sensitivity.Our study identified a prognostic signature linked to metabotropic subtype of CAFs. This signature has promising clinical implications in precision therapy for colorectal cancer liver metastases.